Search clinical trials for: Herceptin (trastuzumab)

Total 1276 results

Samsung Bioepis Co., Ltd.

Completed

A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

HER2 Positive Early or Locally Advanced Breast Cancer

Czechia
Pfizer

Completed

A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)

Healthy

United States
Samsung Bioepis Co., Ltd.

Terminated

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Breast Neoplasms

Ukraine, Romania, Russian Federation, France, Bulgaria, Czechia, Poland
Armando Santoro, MD

Terminated

Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients

NON-SMALL CELL LUNG CANCER

Italy
Shanghai Henlius Biotech

Completed

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects

Healthy

China
Tanvex BioPharma USA, Inc.

Completed

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast Cancer

Belarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
Fudan University
Hoffmann-La Roche

Unknown

Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer (PCH)

Breast Cancer

China
Hoffmann-La Roche

Completed

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

Breast Cancer

Italy, Austria, Belgium, Germany, Spain, United Kingdom, Hungary, Poland, Sweden
Hoffmann-La Roche

Terminated

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

Gastric Cancer

India
Regione Lombardia
Mario Negri Institute for Pharmacological Research; Istituto Clinico Humanitas

Unknown

Trastuzumab Optimization Trial in Breast Cancer (TOP)

Metastatic or Locally Advanced Breast Cancer

Italy
M.D. Anderson Cancer Center

Completed

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

Ductal Carcinoma In Situ

United States
Hoffmann-La Roche

Terminated

A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer

Urinary Tract Cancer

Germany
Hoffmann-La Roche

Terminated

A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer

Breast Cancer

Italy
Nantes University Hospital

Terminated

Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)

Relapsed/Refractory Leukemia

France
Jonsson Comprehensive Cancer Center

Completed

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Breast Cancer

United States
Hoffmann-La Roche

Completed

A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe

Healthy Volunteer

New Zealand
Bristol-Myers Squibb

Completed

Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

Breast Cancer

Australia, Hungary, Canada, United Kingdom, Belgium
Hoffmann-La Roche

Completed

THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Breast Cancer

Italy
University of Michigan Rogel Cancer Center

Terminated

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Breast Cancer

United States
Orano Med LLC

Completed

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Stomach Neoplasms | Breast Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Peritoneal Neoplasms

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

Metastatic Breast Cancer | Metastatic Gastric Cancer

China
Xuzhou Medical University

Unknown

Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer

Gastric Cancer

China
Prestige Biopharma Limited

Completed

A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects (TROIKA-1)

Healthy Volunteers

Australia
Biogen

Completed

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Breast Cancer

United States
National University Hospital, Singapore
National University of Singapore

Unknown

NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer

Breast Cancer | Gastric Cancer

Singapore
Spanish Breast Cancer Research Group

Completed

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer (ChangHER-SC)

Breast Cancer

Spain
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Breast Ductal Carcinoma In Situ

United States, Canada, Puerto Rico, Korea, Republic of
Pfizer

Completed

A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)

Healthy

United States
Hoffmann-La Roche

Completed

A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Breast Cancer

Estonia, Hungary, Turkey, Israel, Slovakia, Bulgaria, Lithuania, Macedonia, The Former Yugoslav Republic of
Genor Biopharma Co., Ltd.

Completed

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

Metastatic Breast Cancer

Australia
EirGenix, Inc.

Completed

A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male Volunteers

Healthy
Academisch Medisch Centrum - Universiteit van Amsterdam...
Roche Pharma AG

Completed

Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma (TRAP)

Esophageal Carcinoma

Netherlands
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Advanced Breast Cancer

United States, Switzerland, China, France
Swiss Group for Clinical Cancer Research

Terminated

Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

Breast Cancer

Switzerland, Italy
Alteogen, Inc.
Cristália Produtos Químicos Farmacêuticos Ltda.

Completed

A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects

Healthy
Mylan Pharmaceuticals Inc
Mylan GmbH

Completed

Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion

Healthy
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects

Healthy

Germany
Celltrion
Nippon Kayaku Co., Ltd.

Completed

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

HER2-positive Carcinoma of Breast

Italy, South Africa, Mexico, Japan, Taiwan, Russian Federation, Philippines, Hungary, Romania, Spain, Bosnia and Herzegovina, India, Peru, Ukraine, Latvia, Argentina, Georgia, Belarus, Chile, France, Poland, Portugal
Hoffmann-La Roche

Completed

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)

Breast Neoplasms

Hungary, Italy, United Kingdom, Canada, Czechia, Bulgaria, Croatia, Dominican Republic, France, Germany, Greece, Guatemala, Hong Kong, Indonesia, Ireland, Korea, Republic of, Netherlands, Panama, Peru, Poland, Portugal, Slovakia, Spain and more
Hoffmann-La Roche

Completed

A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants (HOMERUS)

Breast Cancer

Netherlands
Institut Curie
Centre Leon Berard; Institut Bergonié; Hoffmann-La Roche; University Hospital,... and other collaborators

Completed

Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis (HIT)

Metastatic Breast Cancer | Carcinomatous Meningitis

France
Hoffmann-La Roche

Completed

Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma

Gastric Cancer, Gastroesophageal Junction Cancer

France
Maastricht University Medical Center

Completed

Real World Efficiency of Trastuzumab in Early Breast Cancer

Breast Cancer

Netherlands
ARCAGY/ GINECO GROUP
Hoffmann-La Roche

Terminated

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

Ovarian Cancer

France
Pfizer

Completed

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Carcinoma, Metastatic Breast

United States
M.D. Anderson Cancer Center

Completed

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Advanced Cancers

United States
National Cancer Institute (NCI)

Terminated

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent... and other conditions

United States
Hoffmann-La Roche

Completed

A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

Breast Cancer

Belgium, Israel
Hoffmann-La Roche

Terminated

An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (HERODOT)

Breast Cancer

Romania
Hoffmann-La Roche

Completed

An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)

Breast Cancer

United Kingdom

3

Subscribe